Title: Blood vessel wrap

Applicant/Assignee: SUNSHINE HEART COMPANY PTY LTD

Application No.: 10/595602   Filing Date: 28/Oct/2004

Abstract:

A wrap (20) for securing about a blood vessel (36) by encasing a section of the vessel. The wrap (20) being of thin flexible construction having two ends (22, 24) and two sides (26, 28). The wrap (20) is more elastic or stretchable at, near, or along at least some of its sides (22, 24) compared to at, near, or along its center, to provide strain relief from wrapped to unwrapped aorta. The wrap (20) is not inelastic, so that loss of aortic compliance is minimized or enhanced. The wrap (20) is adapted to apply, in use, less compressive force at, near, or along at least some of its sides (22, 24) compared to at, near, or along its center.

Priority: AU20030905992 Applic. Date: 2003-10-30; WO2004AU01484 Applic. Date: 2004-10-28

Inventor: MILLER SCOTT HUGH [AU]; PETERS WILLIAM SUTTLE [NZ]; DE PLATER GEMMA LEIGH [AU]

Title: High citrate dialysate and uses thereof

Applicant/Assignee: ADVANCED RENAL TECHNOLOGIES

Application No.: 10/984374   Filing Date: 08/Nov/2004

Abstract:

The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout.

In these patients, the initial average urea reduction ratio (URR) was 68.5+-5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73+-5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23+-0.19 to 1.34+-0.2 (p=0.01). This increased urea clearance may be the result of the anticoagulant property of citrate maintaining patency of the dialyzer membrane. The increase in pre-dialysis serum HCO3 may represent increased delivery from the dialysate and production from citric acid.

Priority: US19990155514P Applic. Date: 1999-09-22; US2000-667489 Applic. Date: 2000-09-22

Inventor: CALLAN ROBIN [US]; COLE JAMES J [US]

Title: SELF- FLUSHING MEDICAL APPARATUS

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 11/379884   Filing Date: 24/Apr/2006

Abstract:

An apparatus for use in a therapeutic medical procedure that may include an elongate sheath having a longitudinal axis, an outer surface a distal end and a proximal end, the elongate sheath having a first lumen having a first cross-sectional area running from an first opening at the distal end to a first point proximal the distal end and a second lumen fluidly connected to the first lumen, the second lumen having a distal end at or proximal the first point and a second cross-sectional area less than the first cross-sectional area, the second lumen having a portion running generally along the elongate axis

and an elongate member having a first portion having a third cross-sectional area, a proximal end and a distal end and having a therapeutic device disposed on the elongate member proximate the distal end, the therapeutic device having a first configuration having a fourth cross-sectional area, wherein the elongate member is disposed in the first and second lumens and the distal protection device is disposed in the first lumen, wherein when the distal protection device is disposed in the first lumen, the elongate sheath has a second opening proximate and proximal the distal protection device and a third opening proximal the second opening in which the elongate member is partially disposed, and wherein the second opening is in fluid communication with the third opening when the distal protection device is disposed in the first lumen.

Priority:

Inventor: KIM ELIOT T [US]

Title: METHOD FOR ENUMERATION OF MAMMALIAN MICRONUCLEATED ERYTHROCYTE POPULATIONS, WHILE DISTINGUISHING PLATELETS AND/OR PLATELET-ASSOCIATED AGGREGATES

Applicant/Assignee: LITRON LABORATORIES, LTD

Application No.: 12/177352   Filing Date: 22/Jul/2008

Abstract:

A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains DNA (micronuclei) in erythrocyte populations.

Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample. In particular, the use of the second antibody prevents interference by platelet-associated aggregates in the scoring procedures.

Priority: US2004-878456 Applic. Date: 2004-06-28; US20030482678P Applic. Date: 2003-06-26

Inventor: DERTINGER STEPHEN D [US]

Title: Blood cell sorting methods and systems

Applicant/Assignee: THE GENERAL HOSPITAL CORPORATION

Application No.: 11/646985   Filing Date: 28/Dec/2006

Abstract:

The invention relates to methods of isolating white blood cells (WBCs) from a sample, e.g., whole blood, using magnetic particles that specifically bind to WBCs and a series of specific steps and conditions. The methods can include one or more of decreasing the viscosity of the sample prior to WBC isolation, agitating the sample at specified frequencies, and/or using a sample container arranged such that all of the sample is placed in close proximity (e.g., within 5, 2, 1, or 0.5 mm) to the source of the magnetic field. The new methods provide for isolation of WBC preparations with high yield, purity, and viability. The methods are designed for compatibility with automation protocols for rapid processing of multiple samples.

Priority: US20050754426P Applic. Date: 2005-12-28

Inventor: FAUSTMAN DENISE L [US]; BURGER DOUGLAS E [US]

Title: Device for calculating blood flow in an extracorporeal blood circuit, and an apparatus for treatment of blood using the device

Applicant/Assignee: GAMBRO LUNDIA AB

Application No.: 10/975082   Filing Date: 28/Oct/2004

Abstract:

The invention relates to a device for calculating blood flow and to an apparatus for extracorporeal blood treatment provided with the device. The device includes a memory for receiving and storing either a first datum relating to a blood flow removed from the patient Qb, or a second datum relating to a flow of liquid Qt crossing a tract of the extracorporeal circuit, and a third datum relating to a flow of infusion liquid Qinf flowing through the infusion line. The device also comprises a control unit able to calculate the first datum or the second datum as a function of the third datum relating to the flow of infusion liquid Qinf.

Priority: IT2003MO00293 Applic. Date: 2003-10-29; US20040568068P Applic. Date: 2004-05-03

Inventor: FRESSINET JEAN LOUIS [FR]; ZACCARELLI MASSIMO [IT]; ARTIOLI GIANLUCA [IT]; LETTERI JEFFREY J [US]

Title: Thrombolysis and chronic anticoagulation therapy

Applicant/Assignee: BOSTON SCIENTIFIC NEUROMODULATION CORPORATION

Application No.: 11/949752   Filing Date: 03/Dec/2007

Abstract:

Method and systems of treating a patient with at least one of a myocardial infarction, a stroke, and a pulmonary embolism include providing a stimulator coupled to at least one electrode and a catheter, configuring one or more stimulation parameters to treat at least one of a myocardial infarction, a stroke, and a pulmonary embolism, programming the stimulator with the one or more stimulation parameters, delivering with the stimulator via the catheter at least one drug to at least one tissue in accordance with the one or more stimulation parameters, and limiting perfusion of the at least one tissue by delivering electrical stimulation with the stimulator via the at least one electrode to the at least one tissue.

Priority: US2002-285803 Applic. Date: 2002-11-01; US20010340076P Applic. Date: 2001-11-01

Inventor: WHITEHURST TODD K [US]; MCCLURE KELLY H [US]; THACKER JAMES R [US]

Title: Method, system and machine for collecting a biological fluid to which a selected ratio of solution is added

Applicant/Assignee: MACOPHARMA

Application No.: 10/750143   Filing Date: 31/Dec/2003

Abstract:

The invention concerns a method of collecting a biological fluid, in particular blood, with an anticoagulant and/or preservation solution added, in which the biological fluid is collected by natural flow and the anticoagulant and/or preservation solution is added by pumping, the method making provision for measuring the flow of fluid collected and slaving the pumping speed to the measured flow, so as to obtain continuously during collection a given ratio between the quantity of fluid collected and the quantity of anticoagulant and/or preservation solution added. The invention also concerns a collection machine and bag system for implementing the method.

Priority: FR20030001195 Applic. Date: 2003-02-03

Inventor: BEHAGUE MAURICE [FR]; GOUDALIEZ FRANCIS [FR]; VERPOORT THIERRY [FR]

Title: METHOD OF TREATING A BODILY FLUID

Applicant/Assignee: INTEGRATED SENSING SYSTEMS, INC

Application No.: 12/106642   Filing Date: 21/Apr/2008

Abstract:

A method of treating a bodily fluid withdrawn and then returned to a living body. The method involves withdrawing the bodily fluid from the living body and causing the bodily fluid to flow through a treatment system, altering at least the density of the bodily fluid through the action of a second fluid as the bodily fluid flows through the treatment system, sensing at least the density and flow rate of the bodily fluid before the density thereof is altered by the second fluid, sensing at least the density and flow rate of the bodily fluid after the density thereof is altered by the second fluid, sensing at least the density and flow rate of the second fluid, controlling the density and/or flow rate of the second fluid based on the sensed densities and flow rates, and returning the bodily fluid to the living body.

Priority: US2005-160403 Applic. Date: 2005-06-22; US20040582976P Applic. Date: 2004-06-28

Inventor: SPARKS DOUGLAS RAY [US]; NAJAFI NADER [US]

Title: Nanoparticulate compositions having a peptide as a surface stabilizer

Applicant/Assignee: ELAN PHARMA INTERNATIONAL, LTD

Application No.: 10/978695   Filing Date: 02/Nov/2004

Abstract:

The present invention is directed to nanoparticulate active agent compositions comprising at least one peptide as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.

Priority: US20030517106P Applic. Date: 2003-11-05

Inventor: CUNNINGHAM JAMES [US]; LIVERSIDGE ELAINE MERISKO [US]

Title: BIOBENEFICIAL POLYAMIDE/POLYETHYLENE GLYCOL POLYMERS FOR USE WITH DRUG ELUTING STENTS

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 12/845385   Filing Date: 28/Jul/2010

Abstract:

This disclosure provides a medical device and a method of forming the medical device. The medical device comprises a coating comprising a type-one polymer and a type-two polymer. The type-one polymer comprises at least two different blocks, at least one L1 block with the formula

and at least one L2 block with the formula Medical devices comprising these polymers, mixtures of these polymers with therapeutic agents, and methods of making these polymers and mixtures are within the scope of this disclosure.

Priority: US2008-207419 Applic. Date: 2008- 09-09; US2003-741214 Applic. Date: 2003-12-19

Inventor: PACETTI STEPHEN D [US]

Title: Multiple ratio fluid dispenser

Applicant/Assignee: ARTERIOCYTE MEDICAL SYSTEMS, INC

Application No.: 12/462885   Filing Date: 10/Aug/2009

Abstract:

A double syringe delivery system is disclosed for holding a pair of syringes in a manner so as to accommodate the simultaneous activation of the plunger of each syringe in order to effect simultaneous delivery of the contents of each syringe. The delivery system includes a delivery mechanism for delivering the contents of both syringes to a site of application. The delivery system further includes a support member that is positioned between the two syringe bodies. The elongated support member has resilient, C-shaped clamps on one end of the support member. The clamps are designed to be removably clamped onto the applicator so that the syringe barrels will be held together in a parallel manner. The elongated support member further comprises finger grips. A plunger connects the two syringe plungers so that they can also be simultaneously activated.

Priority: US2004-876147 Applic. Date: 2004-06-24; US2002-212430 Applic. Date: 2002-08-05; US20020388822P Applic. Date: 2002-06-14

Inventor: MCINTOSH KEVIN D [US]; ALBRECHT RICHARD M [US]

Title: Method for separating and purifying RNA

Applicant/Assignee: FUJIFILM CORPORATION

Application No.: 11/995310   Filing Date: 30/Aug/2006

Abstract:

A method for separating and purifying RNA including the steps of passing a sample solution containing a nucleic acid, a washing solution and a recovering solution through a nucleic acid-adsorbing porous membrane to adsorb nucleic, adsorbing, washing and recovering, in which the nucleic acid adsorbing porous membrane is a porous membrane capable of adsorbing a nucleic acid by interaction involving substantially no ionic bond, and the sample solution is obtained by a process, comprising the steps of (I) injecting a test sample containing at least one of blood and leukocyte, and further containing an anticoagulant to a container, (II) adding a hemolytic agent to the container to obtain a leukocyte pellet, (III) adding a nucleic acid-solubilizing reagent to the leukocyte pallet to obtain a mixture solution and (IV)

adding a water-soluble organic solvent to the mixture solution to obtain the sample solution containing the nucleic acid.

Priority: JP20050249694 Applic. Date: 2005-08-30; JP20060229142 Applic. Date: 2006-08-25; WO2006JP317584 Applic. Date: 2006-08-30

Inventor: INOMATA HIROKO [JP]; MORI TOMOKO [JP]

Title: WEARABLE CONTINUOUS RENAL REPLACEMENT THERAPY DEVICE

Applicant/Assignee: NATIONAL QUALITY CARE, INC, FRESENIUS MEDICAL CARE HOLDINGS, INC

Application No.: 11/933533   Filing Date: 01/Nov/2007

Abstract:

A continuous renal replacement therapy (CRRT) device adapted to be worn on a portion of the body of a patient. The CRRT device is worn by the patient and operates on rechargeable batteries for more than 5 hours. Dialysate is used to remove impurities from the blood. The dialysate is recycled and refreshed by a filter section. Less than one liter of dialysate is required to circulate through the wearable CRRT device.

Priority: US2004-940862 Applic. Date: 2004-09-14; US2001-085349 Applic. Date: 2001-11-16

Inventor: GURA VICTOR [US]; RAMBOD EDMOND [US]

Title: WEARABLE ULTRAFILTRATION DEVICE

Applicant/Assignee: NATIONAL QUALITY CARE, INC, FRESENIUS MEDICAL CARE HOLDINGS, INC

Application No.: 11/933569   Filing Date: 01/Nov/2007

Abstract:

An ultrafiltration device adapted to be worn on a portion of the body of a patient includes a blood inlet tube leading from a first blood vessel, a blood pump, an anticoagulant reservoir for infusing anticoagulants into the blood, a blood filter including a substrate through which the blood is circulated and filtered, a fluid bag for storing the excess fluid and a blood outlet tube leading to a second blood vessel.

Priority: US2004-846618 Applic. Date: 2004-05-17; US2001-085349 Applic. Date: 2001-11- 16

Inventor: GURA VICTOR [US]; RAMBOD EDMOND [US]

Title: Flowable carrier matrix and methods for delivering to a patient

Applicant/Assignee: WARSAW ORTHOPEDIC, INC

Application No.: 12/634323   Filing Date: 09/Dec/2009

Abstract:

A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site.

Priority: US2006-504363 Applic. Date: 2006-08-14

Inventor: BEALS NEIL B [US]; SCIFERT JEFFREY L [US]; BODEN SCOTT D [US]

Title: Method and apparatus for determining anticoagulant therapy factors

Applicant/Assignee:

Application No.: 12/378456   Filing Date: 14/Feb/2009

Abstract:

Methods and apparatus are disclosed for determining a new anticoagulant therapy factors for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. New anticoagulant therapy factors maybe based upon the time to maximum acceleration from the time of reagent injection (TX) into a plasma sample, Embodiments include methods and apparatus for determining an anticoagulant therapy factor without requiring use of a mean normal prothrombin time determination or ISI, and may be carried out with the patient sample and a coagulation reagent.

Priority: US2007-906325 Applic. Date: 2007-10-01; US2006-359667 Applic. Date: 2006-02-22; US2003-662043 Applic. Date: 2003-09-12; US2003-428708 Applic. Date: 2003-05-02; US20050679423P Applic. Date: 2005-05-10

Inventor: CARROLL WALLACE E [US]; JACKSON R DAVID [US]

Title: Sealed Sterile System and Method for Filtering Biological or Medical Fluids, in Particular Whole Blood

Applicant/Assignee: GERATEZENTRALE FUR BLUTTRANSFUSION DES OSTERREICHI, FRESENIUS HEMOCARE AUSTRIA GMBH

Application No.: 11/632823   Filing Date: 14/Jun/2005

Abstract:

The invention relates to a sealed, sterile system for filtering fluids, in particular whole blood. The system comprises a first collapsible container for receiving the fluid to be filtered and a second collapsible container for receiving the filtered fluid, both containers interconnected by a fluid line, in which a filter and a third container, for deaeration, are located. The first collapsible container contains a predetermined quantity of air, which is sufficient to ensure that no blood remains in the filter and the adjacent tube line sections when the whole blood is transferred from the first container into the second container. The air that is present in the second container, after the whole blood has been filtered, is transferred to the deaeration container.

Priority: DE200410035352 Applic. Date: 2004-07-21; WO2005EP06338 Applic. Date: 2005-06-14

Inventor: SOMMER CHRISTIAN [AT]; KURZ MICHAEL [AT]; MAYER GUNTER [AT]

Title: Method of making selective organ cooling catheter

Applicant/Assignee: INNERCOOL THERAPIES, INC

Application No.: 11/389879   Filing Date: 27/Mar/2006

Abstract:

A heat transfer device has first and second elongated, articulated segments, each having a turbulence-inducing exterior surface. A flexible joint connects the first and second elongated, articulated segments. An inner coaxial lumen is disposed within the first and second elongated, articulated segments. The inner coaxial lumen is capable of transporting a pressurized working fluid to a distal end of the first elongated, articulated segment.

Priority: US2003-749140 Applic. Date: 2003-12-29; US2001-836585 Applic. Date: 2001-04-16; US2000-566531 Applic. Date: 2000-05-08; US1998-103342 Applic. Date: 1998-06- 23

Inventor: DOBAK III JOHN D [US]; LASHERAS JUAN C [US]

Title: METHODS TO MEASURE IMMUNOSUPPRESSIVE TACROLIMUS, SIROLIMUS, AND CYCLOSPORIN A COMPLEXES IN A BLOOD SAMPLE

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/539825   Filing Date: 12/Aug/2009

Abstract:

The present invention provides methods, diagnostic assays, and diagnostic kits based on said methods, to determine levels of immunosuppressive complexes containing immunosuppressive drugs tacrolimus, sirolimus and cyclosporine A separately and in combination, formed in the blood of a drug-treated patient or in a patient candidate to immunosuppressive drug therapy. These methods, assays and kits are especially useful when using automated systems.

Priority: US2006-398997 Applic. Date: 2006-04-06; US20050668714P Applic. Date: 2005-04-06

Inventor: DRENGLER SUSAN M [US]; BAUGHER BENNETT W [US]

Title: BLOOD TEST APPARATUS

Applicant/Assignee: MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD, PANASONIC CORPORATION

Application No.: 12/159904   Filing Date: 28/Dec/2006

Abstract:

A blood test apparatus wherein a blood collection needle and a blood sensor can be easily attached and detached so that a burden or pain of a patient can be relieved. More specifically speaking, a blood test apparatus wherein a holder, a lancet, a blood collection needle and a blood sensor are united together as a blood sampling cartridge that is detachably mounted to the apparatus body. When this blood sampling cartridge is attached, a plunger involved in the apparatus body holds the lancet and connectors involved in the apparatus body come into contact with the blood sensor. It is preferable that the contact points with the blood sensor of the individual connectors are located at intervals at the same angle centering on a definite point.

Priority: JP20060000354 Applic. Date: 2006-01-05; JP20060000355 Applic. Date: 2006-01-05; JP20060000356 Applic. Date: 2006-01-05; JP20060000357 Applic. Date: 2006-01-05; JP20060000358 Applic. Date: 2006-01-05; JP20060022040 Applic. Date: 2006-01-31; WO2006JP326262 Applic. Date: 2006-12-28

Inventor: FUJIWARA MASAKI [JP]; AKIYAMA TOSHIHIRO [JP]; AMANO YOSHINORI [JP]

Title: Plasma or serum separation membrane and filter apparatus including the plasma or serum separation membrane

Applicant/Assignee: SEKISUI CHEMICAL CO., LTD

Application No.: 10/533539   Filing Date: 02/May/2005

Abstract:

A Plasma or serum separation membrane that enables omitting centrifugal separation, is free from hemolysis attributed to destruction of red blood cells and realizes easy and rapid separation of plasma or serum from blood

and a filter apparatus including the plasma or serum separation membrane. In particular, a plasma or serum separation membrane being a membrane for separation of plasma or serum from blood and having a void ratio of 30% or below

and a filter apparatus comprising a filter member capable of attaining movement of plasma swifter than movement of blood cells and a plasma or serum separation membrane connected in series with a rear side of the filter member.

Priority: JP20020335606 Applic. Date: 2002-11-19; JP20020335607 Applic. Date: 2002-11-19; JP20030124335 Applic. Date: 2003-04-28; WO2003JP14625 Applic. Date: 2003-11- 18

Inventor: TOGAWA KATSUYA [JP]; OKAMOTO RYUSUKE [JP]; ISOGAWA HIRONOBU [JP]

Title: Method enabling the use of extracellular ribonucleic acid (RNA) extracted from plasma of serum to detect, monitor or evaluate cancer or premalignant conditions

Applicant/Assignee: ONCOMEDX, INC

Application No.: 11/364842   Filing Date: 28/Feb/2006

Abstract:

This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

Priority: US2005-216858 Applic. Date: 2005-08-31; US2001- 013868 Applic. Date: 2001-10-30; US1998-155152 Applic. Date: 1998-09-22; WO1997US03479 Applic. Date: 1997-03-14; US19960014730P Applic. Date: 1996-03-26

Inventor: KOPRESKI MICHAEL [US]

Title: Device and method for high-throughput quantification of mRNA from whole blood

Applicant/Assignee: HITACHI CHEMICAL CO., LTD, HITACHI CHEMICAL RESEARCH CENTER

Application No.: 11/803593   Filing Date: 15/May/2007

Abstract:

Disclosed are a method, device kit, and automated system for simple, reproducible, and high-throughput quantification of mRNA from whole blood. More particularly, the method, device, kit and automated system involve combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.

Priority: US2004-796298 Applic. Date: 2004-03-09; US2003-698967 Applic. Date: 2003-10-30; WO2003US12895 Applic. Date: 2003-04-24; US20020375472P Applic. Date: 2002-04- 24

Inventor: MITSUHASHI MASATO [US]

Title: Implantable Prosthetic Valve

Applicant/Assignee: CLINASYS LLC

Application No.: 12/158747   Filing Date: 22/Dec/2006

Abstract:

An implantable prosthetic valve for regulating fluid flow through a body vessel is provided. The prosthetic valve comprises an anchoring member, at least one leaflet, and a restraining member capable of temporarily preventing substantial movement of the leaflet between and open and closed position so as to allow fluid flow in the antegrade and retrograde directions. In various embodiments, the prosthetic valve reduces the risk of thrombosis. In various embodiments, the prosthetic valve reduces the appearance of potentially thrombogenic abnormal flow patterns at the site of implantation immediately following the implantation, allows cell deposition making the valve more biocompatible, less thrombogenic before flow changes resulting from valving action set in and allows tissue growth so that a partially or completely biological functioning valve may form on the scaffold provided by the implant.

Priority: US20050753716P Applic. Date: 2005-12-23; WO2006US48799 Applic. Date: 2006-12-22

Inventor: MERETEI ATTILA [US]

Title: METHOD FOR TESTING EFFICACY OF ANTITHROMBOTIC AGENT

Applicant/Assignee:

Application No.: 11/915273   Filing Date: 08/Nov/2005

Abstract:

The present invention provides a method for testing quickly and easily the manner in which an antithrombotic agent inhibits the acceleration of blood coagulation when a platelet agonist causes acceleration of blood coagulation. The invention is a test method wherein a system in which an anticoagulant is added to a portion of blood sampled from a patient being administered an antithrombotic agent (X system blood), and a system in which an anticoagulant and adenosine diphosphate or collagen are added to a portion of the abovementioned blood (Y system blood) are simultaneously measured by thromboelastograph

and the efficacy of the antithrombotic agent is assessed by comparing the R values of the X system blood and the Y system blood. If the R value of the Y system blood is not found to differ significantly from the R value of the X system blood, the drug is judged to be working.

Adenosine diphosphate and collagen can be used as the anticoagulant. The present invention provides a heretofore unknown method for easily assessing the efficacy of an antithrombotic agent.

Priority: JP20050149183 Applic. Date: 2005- 05-23; WO2005JP20421 Applic. Date: 2005-11-08

Inventor: KAWASAKI JUN [JP]; TANAKA KENICHI [JP]

Title: Cooled ablation catheter with reciprocating flow

Applicant/Assignee: ST. JUDE MEDICAL, ARTIAL FIBRILLATION DIVSION, INC

Application No.: 11/646255   Filing Date: 28/Dec/2006

Abstract:

The invention relates to an ablation catheter which controls the temperature and reduces the coagulation of biological fluids on an electrode of a catheter, prevents the impedance rise of tissue in contact with the electrode, and maximizes the potential energy transfer to the tissue, thereby allowing an increase in the lesion size produced by the ablation. The electrode includes passages positioned to allow blood and other biological fluids to flow into and out of an inner cavity of the electrode. This fluid flow produced the desired cooling effect and is accomplished, for example, by a reciprocating plunger or piston, or by a balloon that is alternately inflated and deflated.

Priority:

Inventor: WANG HUISUN [US]; DANDO JEREMY D [US]

Title: Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique

Applicant/Assignee: ANTISENSE PHARMA GMBH

Application No.: 10/420094   Filing Date: 22/Apr/2003

Abstract:

The present invention is directed to a device for a portable convection enhanced delivery system that allows administering liquids to specific locations within the body, especially tissues and tumors also allowing outsubject treatment. The application system comprises a portable extracorporal pump with a fluid reservoir that is connected via an infusion system to an infusion catheter placeable to any tissue or tumor the fluid should be administered to by high flow microperfusion. The system enables administration of fluids of any kind by convection enhanced delivery also in out-patient treatment. The system can be used for delivering various drugs, proteins, protein toxins, antibodies-for treatment or imaging, proteins in enzyme replacement therapy, growth factors and viruses or oligonucleotides in gene therapy etc.

The application methods as well as the surgical method to implant this device are enclosed to this invention.

Priority:

Inventor: KUNST MECHTHILD [DE]

Title: DIRECT DETERMINATION OF VITAMIN D IN SERUM OR PLASMA

Applicant/Assignee: IMMUNDIAGNOSTIK AG

Application No.: 12/517754   Filing Date: 30/Jan/2008

Abstract:

A method for quantitating vitamin D metabolites directly in blood plasma or serum, without the need for prior purification of the vitamin D metabolites, comprising a digestion of the serum proteins with a serine protease such as proteinase K and sequence of steps for inhibiting the proteinase K activity in the competitive binding analysis. The advantages of this method are its high accuracy over the whole range of physiologically relevant values and that it can be easily adapted for a fully automated analysis of serum and plasma samples.

Priority: DE200710005099 Applic. Date: 2007-02-01; WO2008EP51162 Applic. Date: 2008-01-30

Inventor: ARMBRUSTER FRANZ PAUL [DE]; ROTH HEINZ-JUERGEN [DE]; FRIEDL SABINE [DE]; SCHUMANN CLAUDIA [DE]

Title: Device and method for high-throughput quantification of mRNA from whole blood

Applicant/Assignee: HITACHI CHEMICAL CO., LTD, HITACHI CHEMICAL RESEARCH CENTER

Application No.: 11/525515   Filing Date: 22/Sep/2006

Abstract:

Disclosed are a method, device kit, and automated system for simple, reproducible, and high-throughput quantification of mRNA from whole blood. More particularly, the method, device, kit and automated system involve combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.

Priority: US2004-796298 Applic. Date: 2004-03-09; US2003-698967 Applic. Date: 2003-10-30; WO2003US12895 Applic. Date: 2003-04-24; US20020375472P Applic. Date: 2002-04- 24

Inventor: MITSUHASHI MASATO [US]

Title: Intravascular Line and Port Cleaning Methods, Methods of Administering an Agent Intravascularly, Methods of Obtaining/Testing Blood, and Devices for Performing Such Methods

Applicant/Assignee: HYPROTEK, INC

Application No.: 12/211723   Filing Date: 16/Sep/2008

Abstract:

An intravascular port access device includes a first component having a chamber configured to attach reversibly to an intravenous line port. A second component reversibly attaches to the first component and contains a disinfecting agent and an applicator material. The second component is configured to be reversibly received over external surfaces of the intravenous line port. A method of cleansing an intravenous line port includes providing a port cleaning device having a first component with a chamber containing a first cleaning agent. A second component includes a second cleaning agent. A third component has a microbiocidal agent and is reversibly attached to the first component.

The second component is removed from the device, the external surfaces of the port are contacted with the second cleaning agent, the first cleaning agent is ejected from the chamber into the port, and the third component is used to cap the port.

Priority: US2007-745843 Applic. Date: 2007-05-08; US20060747606P Applic. Date: 2006-05-18; US20060842194P Applic. Date: 2006-08-31; US20070895621P Applic. Date: 2007-03-19

Inventor: TENNICAN PATRICK O [US]

Title: Device and method for high-throughput quantification of mRNA from whole blood

Applicant/Assignee: HITACHI CHEMICAL CO., LTD, HITACHI CHEMICAL RESEARCH CENTER

Application No.: 11/803663   Filing Date: 15/May/2007

Abstract:

Disclosed are a method, device kit, and automated system for simple, reproducible, and high-throughput quantification of mRNA from whole blood. More particularly, the method, device, kit and automated system involve combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.

Priority: US2004-796298 Applic. Date: 2004-03-09; US2003-698967 Applic. Date: 2003-10-30; WO2003US12895 Applic. Date: 2003-04-24; US20020375472P Applic. Date: 2002-04- 24

Inventor: MITSUHASHI MASATO [US]

Title: Protease Inhibitor Sample Collection System

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 12/629158   Filing Date: 02/Dec/2009

Abstract:

A collection container and a method for collecting a biological sample, particularly whole blood, includes at least one stabilizing agent in an amount effective to stabilize and inhibit protein degradation and/or fragmentation. The stabilizing agent is able to stabilize proteases in the biological sample, particularly at the point of collection, by inhibiting protein degradation and/or fragmentation in the sample when the sample is stored. The stabilizing agent includes one or more protease inhibitors.

Priority: US2007- 937954 Applic. Date: 2007-11-09; US2003-436263 Applic. Date: 2003-05-13; US20020379399P Applic. Date: 2002-05-13

Inventor: HAYWOOD BRUCE [US]; DASTANE AJIT [US]; LIN FU-CHUNG [US]

Title: NANOPARTICULATE COMPOSITIONS OF MITOGEN-ACTIVATED PROTEIN (MAP) KINASE INHIBITORS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 11/275069   Filing Date: 07/Dec/2005

Abstract:

Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Priority: US2002-323736 Applic. Date: 2002-12-20; US2002-075443 Applic. Date: 2002-02-15; US2000-666539 Applic. Date: 2000-09-21; US2003-392303 Applic. Date: 2003-03-20; US20020365524P Applic. Date: 2002-03-20

Inventor: BOSCH H WILLIAM [US]; CARY GRETA G [US]; HOVEY DOUGLAS C [US]; JAIN RAJEEV A [US]; KLINE LAURA J [US]; MERISKO-LIVERSIDGE ELAINE [US]; OSTRANDER KEVIN D [US]; RYDE NIELS P [US]; RUDDY STEPHEN B [US]

Title: Protocol for Monitoring Direct Thrombin Inhibition

Applicant/Assignee: HAEMOSCOPE CORPORATION, CORA HEALTHCARE, INC

Application No.: 11/753071   Filing Date: 24/May/2007

Abstract:

A hemostasis analyzer, such as the Thrombelastograph TM (TEG TM ) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit evaluation of hemostasis therapies including anticoagulation therapies such as direct thrombin inhibition therapies.

Priority: US2006-608174 Applic. Date: 2006-12-07; US2003-384345 Applic. Date: 2003-03-07; US2000-591371 Applic. Date: 2000-06-09; US1999-255099 Applic. Date: 1999-02-22; US20060803184P Applic. Date: 2006-05-25

Inventor: COHEN ELI [US]; COHEN ROSLYN [US]

Title: Anticoagulant-coated dipstick for use with a blood centrifuge rotor

Applicant/Assignee: IDEXX LABORATORIES, INC

Application No.: 12/290205   Filing Date: 28/Oct/2008

Abstract:

An anticoagulant-coated dipstick is selectively receivable by the central fill port of a rotor of a blood centrifuge. The dipstick includes an elongated, rod-like member having a first axial end and an opposite second axial end, and a cap affixed to the second axial end. At least a portion of a surface of the rod-like member is coated with an anticoagulant. The elongated rod-like member of the dipstick is dimensioned in length and diameter to be receivable through the central fill port of the rotor to contact a blood sample contained therein. The cap is circular in shape, with a diameter that is greater than that of the rotor fill port to entirely cover and seal the fill port to prevent leakage therethrough of a blood sample contained in the rotor, especially when the rotor is gently agitated or inverted.

Priority: US20070000849P Applic. Date: 2007 -10-29

Inventor: DASSA ALYSSA J [US]

Title: BENZENE DERIVATIVE OR SALT THEREOF

Applicant/Assignee: ASTELLAS PHARMA INC

Application No.: 12/091099   Filing Date: 07/Nov/2006

Abstract:

Problem: To provide compounds which have an anticoagulation effect based on their ability to inhibit the activated blood coagulation factor X and are useful as coagulation inhibitors or agents for prevention or treatment for diseases caused by thrombi or emboli. Means for Solution: Benzene derivatives or their salts having a characteristic chemical structure with a phenol ring and a benzene ring bonding to each other via an amide bond, in which the phenol ring further bonds to a benzene ring or a heteroaryl ring via an amide bond. They have an excellent effect of inhibiting the activated blood coagulation factor X, and especially have an excellent oral activity.

Priority: JP20050323491 Applic. Date: 2005-11-08; WO2006JP322133 Applic. Date: 2006-11-07

Inventor: HIRAYAMA FUKUSHI [JP]; FUJIYASU JIRO [JP]; KAGA DAISUKE [JP]; NEGORO KENJI [JP]; SASUGA DAISUKE [JP]; SEKI NORIO [JP]; SUZUKI KEN-ICHI [JP]

Title: Pharmaceutical compositions providing enhanced drug concentrations

Applicant/Assignee: BEND RESEARCH, INC

Application No.: 09/742785   Filing Date: 20/Dec/2000

Abstract:

A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.

Priority: US19990171841P Applic. Date: 1999-12-23

Inventor: CURATOLO WILLIAM J [US]; SHANKER RAVI M [US]; BABCOCK WALTER C [US]; FRIESEN DWAYNE T [US]; NIGHTINGALE JAMES A S [US]; LORENZ DOUGLAS A [US]

Title: Protrudent analyte sensor

Applicant/Assignee: MEDTRONIC MINIMED, INC

Application No.: 11/348894   Filing Date: 07/Feb/2006

Abstract:

The methods and apparatus for detecting an analyte in blood are useful for detecting an analyte in tissue of a subject. The apparatus comprises a sensor, which comprises an elongated conductive material having a protrudent end, the protrudent end comprising an electrode that detects the presence of an analyte

a substrate affixed to the conductive material

and a support having an external surface, a proximal end, and a distal end. The conductive material is positioned on the support and the protrudent end of the conductive material protrudes beyond the distal end of the support. Optionally, the sensor is suspended within the lumen of a venous flow device. Typically, only a portion of the sensor is suspended within the lumen of the venous flow device, said portion comprising the protrudent end of the conductive material.

Alternatively, the conductive material is positioned on the external surface of the intravenous infusion catheter.

Priority: US2004-935954 Applic. Date: 2004-09-08

Inventor: VAN ANTWERP NANNETTE M [US]; HOSS UDO [US]

Title: Method of treating a hematopoietic associated disease or disorder with plasma-depleted, but not erythrocyte -depleted cord blood compositions

Applicant/Assignee: STEMCYTE, INC

Application No.: 11/771942   Filing Date: 29/Jun/2007

Abstract:

The umbilical cord blood (UCB) compositions of the present invention possess the unique features of having plasma that is substantially depleted from the UCB unit and red blood cells (RBC) that are not depleted from the UCB unit. Such UCB units can be prepared by a process that combines plasma depletion with cryopreservation, selection, thawing, and/or transplantation of hematopoietic stem cells to provide superior clinical outcome by maximizing post-processing cell recovery and post-thaw infusion cell dose. Methods for treating a wide variety of malignant diseases and benign diseases associated with the hematopoietic system by administering the UCB compositions of the present invention are also provided.

Priority: US2006-422017 Applic. Date: 2006-06-02; US20050733956P Applic. Date: 2005-11-03; US20050687127P Applic. Date: 2005-06-02

Inventor: CHOW ROBERT [US]

Title: MECHANICAL THROMBECTOMY DEVICE

Applicant/Assignee: COOK INCORPORATED, COOK MEDICAL TECHNOLOGIES LLC

Application No.: 12/245807   Filing Date: 06/Oct/2008

Abstract:

A medical device for removing a thrombus from a blood vessel and a process thereof is presented. The device includes an outer sheath with a plurality of lumens. A wire guide inserted through one of the lumens is used to place the device proximate to a thrombus. A chemical lysing agent is used to at least partially lyse the thrombus. A wire basket extended through the first lumen proximate to the thrombus is translated back and forth to generate a force that may be transmitted to the partially lysed thrombus assisting in the formation of smaller fragments. A vacuum coupled to the distal end of the second lumen is used to remove the lysed thrombus fragments.

Priority:

Inventor: FISCHER JR FRANK J [US]

Title: Plasma- depleted, not erythrocyte-depleted, cord blood compositions and method of making

Applicant/Assignee: STEMCYTE, INC

Application No.: 11/422017   Filing Date: 02/Jun/2006

Abstract:

The umbilical cord blood (UCB) compositions of the present invention possess the unique features of having plasma that is substantially depleted from the UCB unit and red blood cells (RBC) that are not depleted from the UCB unit. Such UCB units can be prepared by a process that combines plasma depletion with cryopreservation, selection, thawing, and/or transplantation of hematopoietic stem cells to provide superior clinical outcome by maximizing post-processing cell recovery and post- thaw infusion cell dose. Methods for treating a wide variety of malignant diseases and benign diseases associated with the hematopoietic system by administering the UCB compositions of the present invention are also provided.

Priority: US2003-367339 Applic. Date: 2003- 02-13; US20050733956P Applic. Date: 2005-11-03; US20050687127P Applic. Date: 2005-06-02; US20020357308P Applic. Date: 2002-02-14

Inventor: CHOW ROBERT [US]

Title: DRUG- RELEASING STENT WITH CERAMIC-CONTAINING LAYER

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 12/777705   Filing Date: 11/May/2010

Abstract:

A vascular or endoluminal stent is adapted to be implanted in a vessel, duct or tract of a human body to maintain an open lumen. The stent includes a base layer of a biologically compatible metal. An intermediate metal particle layer of substantial greater radiopacity overlies the base layer, with particles bonded to the base layer and to each other to leave interstices therebetween as a repository for retaining and dispensing drugs or other agents for time release therefrom. The particles are composed primarily of a noble metal. Exposed surfaces of the particle layer are coated with ceramic-like iridium oxide or titanium nitrate, as a biocompatible material to inhibit irritation of tissue at the inner lining of the vessel when the stent is implanted.

Priority: US2003-651562 Applic. Date: 2003-08 -29; US2000-740570 Applic. Date: 2000-12-18; US1998-059053 Applic. Date: 1998-04- 11

Inventor: ALT ECKHARD [DE]

Title: Method of profiling gene expression in a healthy subject

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/757918   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2009-587384 Applic. Date: 2009-10-06; US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US19990115125P Applic. Date: 1999-01- 06

Inventor: LIEW CHOONG-CHIN [CA]

Title: MEDICAL DEVICE PACKAGE

Applicant/Assignee: TYCO HEALTHCARE GROUP LP

Application No.: 12/528561   Filing Date: 26/Feb/2008

Abstract:

The present disclosure provides a package for a medical device containing a cavity for receiving the medical device, a first closure having a sealed portal therein and a second closure adjacent the first closure.

Priority: US20070904927P Applic. Date: 2007-03-05; WO2008US02458 Applic. Date: 2008-02-26

Inventor: STOPEK JOSHUA B [US]; KIRSCH DAVID [US]

Title: Apparatus and method for in-vivo plasmapheresis using periodic backflush containing anticoagulant

Applicant/Assignee: TRANSVIVO INC, TRANSVIVO, INC

Application No.: 12/353209   Filing Date: 13/Jan/2009

Abstract:

Method for in-vivo plasmapheresis utilizing a plurality of elongated hollow microporous filter fibers periodically interrupt diffusion of blood plasma from a patient, and, for a selected time, directing backflush fluid into the fibers at a pressure and interval sufficient to cleanse the fiber pores, after which plasma diffusion is resumed. The backflush fluid, preferably a normal saline solution, may contain an anticoagulant such as heparin, citrate or NO donor in suitable concentration for systemic anti-coagulation or for treating the fiber for thromboresistance.

Priority: US2005-320866 Applic. Date: 2005-12-29; US2003-408657 Applic. Date: 2003-04-04; US2001-754773 Applic. Date: 2001-01-04

Inventor: GORSUCH REYNOLDS G [US]; COOPER TOMMY GENE [US]; HANDLEY JR HAROLD H [US]; PETERS HAROLD W [US]

Title: Method of storing red blood cells with an acidic additive solution under oxygen depletion

Applicant/Assignee: HEMANEXT LLC, THE TRUSTEES OF BOSTON UNIVERSITY

Application No.: 11/128576   Filing Date: 13/May/2005

Abstract:

There is provided compositions and methods for the storage of red blood cells. The compositions are additive solutions comprising adenine, dextrose, mannitol, NaH2PO4, and optionally NaCl and/or NH4Cl. Composition are preferably used with oxygen- depletion refrigerated storage of red blood cells and may optionally be employed with nutrient supplements extending the useful shelf life of stored blood.

Priority: US2002- 295781 Applic. Date: 2002-11-15; US20010332405P Applic. Date: 2001-11-16

Inventor: BITENSKY MARK W [US]; YOSHIDA TATSURO [US]

Title: GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF

Applicant/Assignee: CELERA CORPORATION

Application No.: 12/403552   Filing Date: 13/Mar/2009

Abstract:

The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

Priority: US20080069687P Applic. Date: 2008-03-13

Inventor: BARE LANCE [US]; DEVLIN JAMES J [US]; ROSENDAAL FRITS R [US]; REITSMA PIETER H [US]; BEZEMER IRENE D [US]

Title: Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism

Applicant/Assignee: LEWIS S. COLEMAN, MD, INC

Application No.: 11/080709   Filing Date: 15/Mar/2005

Abstract:

A method for treating skin malignancies, malignant tumors, metastatic malignancies and abnormal skin growths in an organism by treating the organism to inhibit the stress mechanism via different pathways and synergistically reduce the production of thrombin in the organism by maintaining antinociception anesthesia throughout the treatment process to control psychic and somatic stress and to reduce the activity levels of Factor VIII, administering medications to the organism that reduce the activity of Factor VII, administering anti-thrombin medications to the organism, or administering to the organism medications that reduce the activity levels of Factor X and Factor Xa.

Priority:

Inventor: COLEMAN LEWIS S [US]

Title: OXIDIZED HEPARIN FRACTIONS AND THEIR USE IN INHIBITING ANGIOGENESIS

Applicant/Assignee:

Application No.: 13/029584   Filing Date: 17/Feb/2011

Abstract:

The present invention relates to a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 4,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. The present invention also relates to methods of inhibiting angiogenesis and treating an angiogenesis -mediated disorder in a subject by administering a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 30,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. Another aspect of the present invention relates to compositions including the heparin fractions of the present invention.

Priority: US2003-667216 Applic. Date: 2003-09-19; US20020411851P Applic. Date: 2002-09-20

Inventor: MOUSA SHAKER A [US]

Title: Flowable carrier matrix and methods for delivering to a patient

Applicant/Assignee: WARSAW ORTHOPEDIC, INC, WARSAW OTHOPEDIC, INC

Application No.: 12/977310   Filing Date: 23/Dec/2010

Abstract:

A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site.

Priority: US2009-634323 Applic. Date: 2009-12-09; US2006-504363 Applic. Date: 2006-08-14